Invitation to the Extraordinary Shareholders’ Meeting
Mechelen, Belgium, 31 July 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of subscription rights, holders of convertible bonds, directors and statutory auditor to its extraordinary shareholders' meeting that will be held on Wednesday 2 September 2020 at 9:00 a.m. CEST, at the offices of the Company at Generaal de Wittelaan 11B, 2800 Mechelen, Belgium.
In light of the COVID-19 pandemic, it is currently envisaged that the measures imposed by the Belgian government to deal with this pandemic, such as the obligation to guarantee a distance of 1.5 meters between each person, may still be in effect as of 2 September 2020, date of the Company's extraordinary shareholders' meeting. These measures are in the interest of the health of individual securities holders, as well as of the employees of the Company and others who are responsible for organizing the shareholders' meeting. It can also not be excluded that the Belgian government will again impose additional measures. We will monitor the situation closely and will disclose all relevant information and measures that have an impact on the shareholders' meeting on the Biocartis website.
In view hereof, the Company recommends that the shareholders that wish to participate in the extraordinary shareholders' meeting make use, as much as practically possible, of the right to vote through voting by mail or by proxy to the chairman of the Board of Directors. Furthermore, it is recommended that holders of securities that wish to exercise their right to ask questions regarding the items on the agenda of the extraordinary shareholders' meeting do so in writing. The modalities of the aforementioned means of participation in the extraordinary shareholders' meeting are set out in the convening notice and in the relevant forms for voting by mail or by proxy.
In order to be admitted to the extraordinary shareholders’ meeting, the holders of securities issued by the Company must comply with Article 7:134 of the Belgian Code of Companies and Associations and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the shareholders’ meetings can be consulted on the Company’s website
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.
Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
- Biocartis Group NV
- Biocartis Group NV